Webinar on the use of platform approaches in the non-clinical and clinical domains, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 2 March 2026, 09:25 (CET) to 2 March 2026, 12:30 (CET)

Submitted by Anonymous (not verified) on 25 August 2026 - 10:23

Webinar on the use of platform approaches in the non-clinical and clinical domains, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 2 March 2026, 09:25 (CET) to 2 March 2026, 12:30 (CET)

Human medicines European public assessment report (EPAR): Vpriv, velaglucerase alfa, Date of authorisation: 26/08/2010, Revision: 22, Status: Authorised

Submitted by Anonymous (not verified) on 25 August 2026 - 9:52

Human medicines European public assessment report (EPAR): Vpriv, velaglucerase alfa, Date of authorisation: 26/08/2010, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau), chenodeoxycholic acid, Date of authorisation: 10/04/2017, Revision: 8, Status: Authorised

Submitted by Anonymous (not verified) on 24 August 2026 - 16:40

Human medicines European public assessment report (EPAR): Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau), chenodeoxycholic acid, Date of authorisation: 10/04/2017, Revision: 8, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness